Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
45.93
-0.90 (-1.92%)
Nov 21, 2024, 2:39 PM EST - Market open
Biohaven Employees
Biohaven had 239 employees as of December 31, 2023. The number of employees increased by 37 or 18.32% compared to the previous year.
Employees
239
Change (1Y)
37
Growth (1Y)
18.32%
Revenue / Employee
n/a
Profits / Employee
-$3,365,418
Market Cap
4.64B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Select Medical Holdings | 54,600 |
| Integer Holdings | 10,500 |
| Stevanato Group | 5,634 |
| Oscar Health | 2,400 |
| Alkermes | 2,100 |
| PROCEPT BioRobotics | 626 |
| ADMA Biologics | 624 |
| Axsome Therapeutics | 545 |
BHVN News
- 8 days ago - Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - PRNewsWire
- 7 weeks ago - Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 7 weeks ago - Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - PRNewsWire
- 7 weeks ago - Biohaven Announces Proposed Public Offering of Common Shares - PRNewsWire
- 7 weeks ago - Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine - PRNewsWire
- 2 months ago - Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst - Seeking Alpha
- 2 months ago - Biohaven Stock Soars on Positive Results for Rare Neurological Disease Drug - Investopedia
- 2 months ago - Biohaven Stock Spikes After Drug Candidate To Treat Rare Neurodegenerative Disease Shows Promise - Benzinga